Shanghai Haiyan Pharmaceutical Technology | ApexOnco - Clinical Trials news and analysis

x

“It's very intuitive and always up-to-date”

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

Trial results

24 January 2024

OncoC4 takes its Siglec-10 bet into the clinic

The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.

Subscribe to Shanghai Haiyan Pharmaceutical Technology